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Abstract
Approximately one million deaths are attributed to malaria every year. Latest reports
of multi-drug treatment failure of falciparum malaria underscore the desideratum to
understand  the  molecular  substratum  of  drug  resistance.  The  mutations  in  the
digestive vacuole transmembrane protein Plasmodium falciparum chloroquine resistance
transporter  (PfCRT)  are  mainly  responsible  for  chloroquine  resistance  (CQR)  in
Plasmodium falciparum. Multiple mutations in the PfCRT are concerned in chloroquine
resistance,  but  the evolution of  intricate  haplotypes is  not  yet  well  understood.  P.
falciparum resistance to chloroquine is the standard antimalarial drug and is mediated
primarily by mutant forms of the PfCRT. In this chapter, we present the mechanism
of action of the chloroquine, the structural changes of the gene after the mutations as
well as different haplotypes of the PfCRT.
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1. Introduction
The rapid advancement and spread of malaria parasite along with antimalarial resistance is
becoming a critical disaster to the world health. Chloroquine resistance (CQR) originated in
Southeast Asia and South America, more or less simultaneously, in late 1950s and subse-
quently spread to several other malaria-endemic countries [1]. PfCRT, a candidate gene for
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CQR, is present at the digestive vacuole membrane and it holds 10 putative transmembrane
domains [2, 3].  Mutations in two genes, namely, the Plasmodium falciparum  CQ resistance
transporter (PfCRT) and multidrug resistance transporter-1 (pfmdr1), have been reported as
responsible for CQR in P. falciparum.  In addition, the polymorphisms of the PfCRT gene
produce two different forms of PfCRT based on the drug response class, such as Chloroquine
Sensitive (CQS) and CQR. The point mutations of the PfCRT codons are 72–76, 271, 326, 356,
and 371, whereas two codons responsible for pfmdr1 are 86 and 1246 as molecular markers
of CQ resistance [4]. The position of 72–76 of the PfCRT are considered as molecular markers
used for detecting CQR malaria parasites due to the mutations in the positions 72–76 of the
PfCRT, which were observed as a majority of P. falciparum  endemic areas. There are five
polymorphisms that form different haplotypes vary among the P. falciparum endemic regions.
There  are  three  major  haplotypes  based  on  specific  mutations  such  as  CVIETIHSESI,
CVIETIHSESTI, and SVMNTIHSQDLR [2, 5–7].
Chloroquine was used as a synthetic drug in the early 1950s and 1970s [8]. The resistance to
this drug was reported in Palian area of Cambodia nearer to Thai-Cambodia border as well as
in Latin America. Subsequently the reported resistance to chloroquine in South Asia moved
westward and during 1973, it was found to be present in North East region of India. Subse-
quently it spread to rest of India and beyond [9]. In 1950s, before the chloroquine resistance
became widespread, it was the main drug which was cheap and having least toxicity as well
as highly effective schizonticidal drug and also was effective against all the types of parasite
species affecting human. But appearance of widespread resistance to chloroquine has contrib-
uted to resurgence of malaria in many countries of Asia including India [10].
By late 1980s, chloroquine became more or less obsolete for treating P. falciparum infections
globally. However, due to high economical burden in introducing alternate treatment such as
artesunate combination therapy, etc. for treatment of Plasmodium vivax restricted many
countries like India to continue only with chloroquine for treatment of P. vivax [11]. This dual
drug policy for the treatment of P. falciparum and P. vivax resulted in further consolidation of
P. falciparum-resistant population in various southeastern regions of the Asia, especially in
India [10].
In this chapter, we estimated certain scores of mutations such as (limbo, tango, and waltz score)
to understand the changes that occur to the PfCRT protein after mutation with the help of
homology modeling and single-nucleotide polymorphism (SNP).
2. P. falciparum CRT as a target for antimalarial drug design
Earlier, the parasite proteins involved in the resistance mechanism of malaria were unknown,
but currently, it is well understood that the mutations in the PfCRT gene are causally involved
in various methods such as in vitro and in vivo resistance as well as altered drug accumulation
[2, 3, 12]. Identification of PfCRT gene, which encodes a putative transporter or channel protein,
was a major achievement in the search for the genetic basis of CQR in P. falciparum [2]. PfCRT
is a 48-kDa protein having 424 amino acids, 13 exon gene spanning 36 kb of chromosome 7
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and 10 predicted transmembrane-spanning domains and is confined in a small area to the
Digestive Vacuole (DV) membrane in erythrocytic stage parasites [2, 3]. The polymorphisms
of PfCRT segregate precisely with two distinct drug response, which is considered either CQS
or CQR. Fifteen polymorphic amino acid positions in PfCRT are associated with CQR in field
isolates. These vary significantly depending on the geographic location and selection history,
while CQS strains maintain an invariable wild-type allele [5–6, 13, 14]. K76T and S163R
mutations in PfCRTCQR are primary and necessary for the resistance phenotype, which is the
most reliable molecular marker of resistance among the various PfCRT mutations [10, 15, 16].
The endogenous role of PfCRT in the malaria parasite has not been clear yet despite the wealth
of epidemiological and in vitro drug response data demonstrating the critical role of PfCRT
mutations in producing CQR. An understanding of the natural role of PfCRT in a normally
functioning cell is indeed needed to provide a clearer picture of how drug resistance works in
the malaria parasite. Muhamad et al. studied the polymorphic pattern of PfCRT, which may
be applied surveillance of chloroquine [17].
3. Mechanism of PfCRT
The mechanism involved in resistance against quinoline containing compound CQ in P.
falciparum is still unclear [18, 19] and indeed the mode of action of this antimalarial chemo-
therapeutic agent is not beyond the debate. Chloroquine is thought to accumulate in high levels
in the food vacuole of the asexual erythrocytic malaria parasites, where it acts by interfering
with the polymerization of heme (hematin) into the hemozoin. The malaria parasite feeds by
degrading hemoglobin of host cell, producing free ferriprotoporphyrin IX (FP) as a by-product.
Ferriprotoporphyrin IX (FP) is highly toxic to the parasite and is neutralized via a process of
biomineralization (polymerization) to form innocuous hemozoin crystals (β-hematin) known
as malaria pigment. Chloroquine is thought to inhibit parasite growth by inhibiting the
detoxification of ferriprotoporphyrin IX (FP) [20–23]. Chloroquine (CQ) appears to trap FP in
a μ-oxodimeric form and prevents the formation of the β-hematin dimers that are required for
hemozoin formation [24]. Thus, CQ causes a buildup of toxic FP molecules that eventually
destroy the integrity of malaria parasite protein and membranes [25].
Current studies highlight an important gene connected to the resistance, P. falciparum chloro-
quine resistance transporter (PfCRT). It encodes a new transporter and also differentiates
between the global selective sweeps of different haplotypes having the mutation, K76T [26].
The PfCRT gene which produces the transport proteins on the plasma membrane of the
parasite’s food vacuole, have been confirmed of involving with the resistance of the parasite
to antimalarial drugs [27].
The mechanisms involved in the development of CQ resistance are also unclear. It is postulated
that CQ resistance could arise as a consequence of any phenotypic and genotypic alteration(s),
which reduces the concentration of the drug in the food vacuole of the parasite. This leads to
a change in parasite biology and can lead to reduced uptake of the drug or enhanced CQ efflux
from the cell or a combination of both resulting in reduced accumulation of drug inside the
Structure and Functional Differentiation of PfCRT Mutation in Chloroquine Resistance (CQR)...
http://dx.doi.org/10.5772/64659
147
digestive vacuole of the parasite. It has been established that in CQ-resistant parasites, the
accumulation of chloroquine inside the vacuole is significantly less than that in CQ-sensitive
parasites [28, 29]. It was originally thought that this lack of accumulation was due to the result
of an efflux mechanism, and P-glycoprotein was implicated as the pump responsible for the
efflux. However subsequent studies have suggested that efflux rates of CQ-resistant and CQ-
sensitive strains are similar. So it appears that CQ resistance involves a diminished level of
drug uptake rather than, or as well as, enhanced efflux. Chloroquine-resistant parasites are
known to get rid themselves of the drugs 40–50 times faster than sensitive parasites [30] but
the biochemical basis of this efflux is not clear. The efflux of chloroquine and in fact the entire
chloroquine-resistant phenotype can be reversed with Ca+ channel blockers such as verapamil
and diltiazem [31]. This phenomenon is biologically very similar to multi-drug resistance
(MDR) phenotype of mammalian tumor cells, where a wide spectrum of chemotherapeutic
agents is expelled from the cells by a verapamil-sensitive pump [32–35]. Verapamil (VPL),
which inhibits P-glycoprotein (encoded by mdr gene) mediated multi-drug resistance (MDR)
in mammalian tumor cells, also partly reverses chloroquine resistance in malaria parasites
grown in vitro [31]. Because this reversal phenomenon is in some ways analogous to the reversal
of MDR in mammalian tumor cell lines, CQ resistance has been postulated to involve an energy
driven P-glycoprotein pump similar to that encoded by the mammalian mdr gene [31]. Two
P. falciparum genes, which are homolog to mammalian mdr, have been identified and mapped
to chromosome 5 and named pfmdr1 and pfmdr2 [36–38]. Associations have been reported
between chloroquine resistance and mutations or amplification of the mdr-like gene pfmdr1,
which encodes P-glycoprotein homolog-1 (Pgh1) [36, 39], which has been found to be located
in the food vacuole membrane of the erythrocytic stages of the parasite [40], suggesting that it
could be involved in drug transport across this membrane [41]. DNA sequencing of the pfmdr1
gene from reference strains and field isolates has revealed several point mutations that
correlated with CQ resistance [39]. In earlier studies, several point mutations or nucleotide
changes at position 754, 1049, 3598, 3622, and 4234 in pfmdr1 gene resulting in amino acid
change at codons 86, 184, 1034, 1042, and 1246, respectively, have been shown to be associated
with CQ resistance [42, 43]. But the role of these mutations in pfmdr1 in CQ resistance is
controversial [44–51]. It has been observed that most of the southeast Asian CQ-resistant
isolates (K1 genotype, on the basis of 3′ polymorphism in pfmdr1) have the mutation at
nucleotide 754 resulting in amino acid change at codon 86 from asparagines to tyrosine (N86Y)
while CQ-resistant South American isolates (7G8 genotype based on 3′ polymorphism in
pfmdr1) have not shown mutation at codon 86 but mutational change at codon 184, 1034, 1042,
and 1246 have been shown. Out of these several mutations described, the mutation at codon
86 appears to be an important, as this may be involved in substrate specificity of the gene
product (P-glycoprotein) and may alter the transport activity of the protein [52]. Moreover,
mutation at codon 86 has also been correlated to CQ resistance in parasites selected in vitro for
CQ resistance [53]. However, studies from different geographical areas of the world have given
the controversial picture of this mutation. Some field studies have confirmed the presence of
this mutation in chloroquine-resistant isolates from Malaysia [42], Nigeria [54] Guinea-Bissau
[55], and sub-Saharan Africa [56]. No association with this mutation, however, was found in
isolates from Sudan [44], Thailand [45], and Cambodia [46]. Moreover, genetic studies found
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no linkage between chloroquine resistance and the pfmdr1 gene [57]. In India, Bhattacharya
and Pillai have found strong association between chloroquine resistance and certain mutations
in the pfmdr1 gene of P. falciparum isolates [58]. However, that study was conducted in small
number P. falciparum strains. Gómez-Saladín et al. found the involvement of tyr86 mutation of
pfmdr1 gene in CQ resistance but no significant association between tyr86 mutation and level
of resistance with chloroquine [59]. Majority of pfmdr1 studies reported till date have indicated
conflicting pieces of evidence, which suggest that CQ resistance in P. falciparum involves
multiple transport mechanisms and multiple genes.
Another locus governing chloroquine resistance in a P. falciparum genetic cross has been
mapped on chromosome 7 and has been named as cg2 (candidate gene) [57, 60]. A protein
specified by this gene has size variation in three repeat regions (k, φ, and ω) several non-silent
point mutations and size variation in a central poly-Asn tract. Recently, field studies have
identified a series of mutations in cg2 gene in chloroquine-resistant P. falciparum strains
suggesting that polymorphism in cg2 gene was highly associated with CQ resistance [61, 62].
Chloroquine-resistant strains have been found to consist of 16 tandem repeat units in omega
repeat region (Dd2 type) of cg2 gene, while the chloroquine-sensitive strains have either ≤15
or ≥17 repeat units [54]. A significant but incomplete association has been found between the
presence of the cg2 Dd2-like omega repeat length polymorphism and in vitro resistance and
between the tyr86 allele of pfmdr1 and in vitro resistance [49]. Adagu and Warhurst have
reported the ala281 mutation in cg2 gene and Dd2-type kappa (k) repeats in CQ-resistant
isolates of northern Nigeria [62]. They have also reported the significant association between
tyr86 mutation in pfmdr1 and Dd2-type kappa (k) repeat and ala 281 mutation of cg2 gene.
Recently PfCRT, a gene with 13 exons, has been identified near cg2 on chromosome 7 [2]. This
gene encodes, a transmembrane protein “PfCRT” in the digestive vacuole of malaria parasites.
Sets of point mutations in PfCRT were associated with in vitro chloroquine resistance in clinical
isolates and laboratory lines of P. falciparum from Africa, South America, and southeast Asia
[7, 12, 14, 63–66]. One mutation, the substitution of lysine (K76) by threonine (T76) at position
76 (K76T), was present in all resistant isolates and absent in all sensitive isolates tested in vitro
[12, 14, 64, 66–69]. A significant association was found between an allele of the P. falciparum
chloroquine resistance transporter gene (PfCRT-T76) with both in vitro and in vivo resistance
and a significant association between pfmdr1-tyr86 and PfCRT-T76 has also been observed
among resistant isolates, which suggests a joint action of the two genes in high-level CQ
resistance [65]. Furthermore, it has also been observed that although the PfCRT-K76T mutation
was present in all CQ-resistant isolates, yet this mutation was also present in patients who
recovered clinically after CQ therapy [68, 70]. Hence, it has been suggested that other mecha-
nism(s) might be involved in modulating outcome of therapy in such cases [64].
The nature of these genetic polymorphisms and their relationship with drug-resistant strains
has not been studied in Indian strains of P. falciparum. Further, a specific marker capable of
diagnosing a chloroquine resistance is yet not available. It was therefore, important to inves-
tigate whether the CQ-resistant P. falciparum parasites could be identified directly from a blood
sample by a rapid, sensitive, and specific method like PCR, which may be of great help in
prompt treatment of falciparum malaria, particularly the severe and complicated one.
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Therefore, the present study was undertaken to investigate the mutation(s) and genetic
polymorphism(s) in the gene PfCRT.
There is a divergence in the literature for the exact mechanism of PfCRT-producing CQR. One
theory is that by using energy to transport CQ out of the DV, the protein mediates active drug
efflux (similar to that of HuMDR1), which makes it away of its targets [71]. Mutations in the
protein may alter its substrate specificity by using this model, which leads to greater CQ affinity
for mutant isoforms.
One more hypothesis is that PfCRT facilitates the diffusion of the charged drug species (which
is also known as “charged drug leak” hypothesis; [72, 73]). Inside the acidic DV, the drug
molecules present are charged as compared to the outside of the DV, which neglects the drug
binding. The charged molecules require some kind of carrier as they cannot pass through the
hydrophobic environment of a membrane. A benefit of this suggestion is that it provides an
explanation for the significance of the K76T mutation. In this mutation, the lysine in wild-type
CQS isoforms has a basic side group having positive charge that repels protonated CQ, while
the neutral threonine allows for an open pore through which charged CQ may pass.
Another mechanism is there based on the pH alterations of the DV, which may be influenced
by PfCRT. It has been shown that CQR parasites have a more acidic DV than CQS parasites by
calculating the pH of the DV [74], which is very surprising because at low pH weak base
partitioning would predict increased drug accumulation. However, the rates of hematin
aggregation and hemozoin formation are increased at acidic pH; as a result, it would reduce
the quantity of target available for CQ binding [2]. The amount of surplus unbound drug may
alter the equilibrium of passive drug accumulation [73] or may be transported out of the DV
by mutant PfCRT [75].
4. Structure of P. falciparum CRT and its mutants
The PfCRT gene identified as the determinant gene for CQR gene since the genetic cross
between a CQR clone of Indochina (Dd2) and a CQS clone of Honduras (HB3) [57]. The PfCRT
protein is of 48.6 kDa, which contains 424 amino acids encoded by a 13 exon gene in the
chromosome having 36-kb segment (Figure 1) [2]. It may catalyze chloroquine quinine flux
Figure 1. The homology model of the protein using the genebank sequence.
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with H+ across the digestive vacuole membrane having with 10 putative TMSs [76]. Nessler et
al. observed activate various endogenous transporters in frog oocytes, which helps in trans-
porting quinoline drugs including quinine and quinidine [77]. The drug specificity that
determines levels of accumulation is because of the mutations in TMSs 1, 4, and 9 alter, which
builds an idea of these TMSs play a role in substrate binding [78]. The substrates responsible
for PfCRT mutants are chloroquine-resistant reversers [79].
Rapid progressions of chloroquine resistance (CQR) have activated the identification of some
other genetic target(s) in genome of P. falciparum such as the mutation in K76T of PfCRT gene
including three other positions 72, 74, and 75 [80]. The three mutations may present high
resistance to CQ than the K76T mutant [81].
The protein is a member of the drug metabolite transporter (DMT) superfamily (TC #2.A.7)
[82]. PfCRT contains drug/metabolite transporter domain. This domain is found in protein
which is engaged in pectinase, cellulase, and blue pigment regulation. In plasmodium species,
the PfCRT is situated at the intra-erythrocytic digestive vacuole. Mutations in this protein
present verapamil-reversible chloroquine resistance to P. falciparum. The mutations in PfCRT
result in increased compartment acidification. PfCRT-cognate vicissitudes in chloroquine
replication involve altered drug flux across the parasite digestive vacuole membrane. Bray et
al., concluded that PfCRT is mediated by the efflux of chloroquine from the digestive vacuole
[72].
5. Analysis of single nucleotide variants scores
Three parameters have been considered for the estimation of structural changes of the PfCRT
gene such as aggregation prediction (TANGO), amyloid prediction (WALTZ), and chaperone-
binding prediction (LIMBO). SNPeffect 4.0: online prediction of molecular and structural
effects of protein-coding variants was used for the study [83]. The three different positions of
PfCRT gene were mutated manually in the protein sequence, that is, at 74, 75, and 76 positions.
The mutated and the wild-type proteins were further processed using the SNPeffect software
to calculate the difference in TANGO, WALTZ, and LIMBO score. The TANGO score obtained
for the mutation of M74I, N75E, and K76T is given in Figure 2. The WALTZ scores of the wild
type and the mutants are given in Figure 3. The LIMBO scores are given in Figure 4.
Figure 2. The aggregation prediction showing the differences of LIMBO scores of the wild-type PfCRT with the mu-
tants.
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Figure 3. The amyloid prediction showing the differences of LIMBO scores of the wild-type PfCRT with the mutants.
Figure 4. The chaperone-binding prediction showing the differences of LIMBO scores of the wild-type PfCRT with the
mutants.
6. The multiple haplotypes of PfCRT
In South America and southeast Asia, the CQR P. falciparum was first came into sight in the late
1950s and early 1960s, leading to the suggestion of Su et al., that resistance rises from two
independent basic events [61]. Further studies have been done to analyze a huge number of
geographically diversed PfCRT alleles and microsatellite genotypes from parasite isolates have
identified at least three additional independent foci of resistance [5, 6]. CQR creation has been
discovered in the Thai-Cambodian border region still now (eventually spreading westward
into Africa), Papua New Guinea, the Philippines, Colombia, and Peru [84].
Cooper et al. revealed that 21 exclusive CQR PfCRT protein sequences are identified from field
isolates and two additional haplotypes have been created using CQ selective pressure on the
106/1 parasite line in laboratory [3]. It is impossible to differentiate the CQR foci or the genetic
variations of the subsequent involved in one origin without understanding performing the
whole analysis of the PfCRT sequence and its surrounding loci by means of microsatellite
typing. Johnson et al. developed four unique CQS haplotypes using the drug selection
procedures of a laboratory [85].
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Based on different geographical locations, the existence of the three PfCRT haplotypes
revealed. According to Su et al. and Wootton et al. the first and the oldest resistant haplotype
is CVIETIHSESII (amino acids 72–73–74–75–76–77–97–220–271–326–356–371), which exists in
the FCB line of southeast Asia and is found in African isolates such as RB8, with consistency
of spreading the CQR from Asia to Africa [5, 61]. The second haplotype is CVIETIHSESTI,
which is found in the 102/1 Sudan strain, illustrated the characteristics of the isolates such as
Dd2 from Thailand, and is newly explained the PH4 isolate from Morong, Philippines [2, 6].
An older PfCRT haplotype is CVIET found in South America, which implies that it may be
because of the traveler who recently traveled to the location [86]. The third haplotype is
detected in the INDO19, FCQ22, and 7G8 isolate line from Thailand, Papua New Guinea, and
Brazil, respectively, and is reported as SVMNTIHSQDLR [2, 6, 7].
Different mutations in the PfCRT gene which change the nucleotide sequence into different
genes and form different haplotypes are very general with the incidence of chloroquine
resistant (CQR) [87].
7. Conclusion
The haplotype variations of PfCRT broadly classified into three groups, namely southeast
Asian, Latin America, and Papua new guinea. This is used as a marker in the study of P.
falciparum population diversity along with other markers. It is noteworthy to point out that
PfCRT plays an important role in CQ transport and intracellular pH (pHi) regulation in
parasite and the problem of drug resistance to antimalarials. In order to study the functions
of wild-type PfCRT and mutants of PfCRT, calculation of different structural estimation score
were generated where it showed that there is a notable variation in LIMBO, TANGO, and
WALTZ scores.
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